Enzon PEG-ADA orphan product grant
The "Severe Combined Immunogencity Disease: Enzyme Therapy" grant provides a total of $169,908 for a three year period to fund the on-going development of the orphan PEG-adenosine deaminase (PEG-ADA) for treatment of children with Severe Combined Immunodeficiency Disease (SCID). FDA designated PEG-ADA an orphan product in 1985.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.